ACT acquires license to anticancer drug from Brown Cancer Center

Researchers at Brown Cancer Center have discovered that 3PO inhibits a key enzyme, PFKFB3, which suppresses both sugar metabolism and cell proliferation among cancer cells. In addition, 3PO blocks PFKFB3 from signaling to cancer cells to spread or proliferate. The University of Louisville researchers have shown in the laboratory that 3PO could be a promising anti-cancer therapeutic against cancers such as leukemia and solid tumors.

Randall Riggs, president & CEO of ACT, said: “We are very excited to have the opportunity to advance this leading edge drug discovery through early clinical development, then to the pharmaceutical industry, and ultimately to the patients who need it.”